您当前的位置:

Belnacasan

(Synonyms: VX-765)
目录号: PL03259 纯度: ≥99%
Belnacasan (VX-765) 是 VRT-043198 的口服生物活性前药,VRT-043198 是有效选择性的 IL 转换酶 (ICE)/caspase-1 抑制剂,对 caspase-1 的 Ki 值为 0.8 nM,对 caspase-4 的 Ki 值小于 0.6 nM。Belnacasan (VX-765) 作用于外周血单核细胞,可抑制 LPS 诱导的 IL-1β 和 IL-18 释放,IC50 约为 0.7 μM。
CAS No. :273404-37-8
商品编号 规格 价格 会员价 是否有货 数量
PL03259-5mg 5mg ¥642.00 请登录
PL03259-10mg 10mg ¥893.00 请登录
PL03259-25mg 25mg ¥1775.00 请登录
PL03259-50mg 50mg ¥2985.00 请登录
PL03259-100mg 100mg ¥3845.00 请登录
PL03259-200mg 200mg ¥5515.00 请登录
PL03259-500mg 500mg 询价 询价
PL03259-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1475.00 请登录
PL03259-1 mL x 10 mM (in DMSO) ¥757.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
*注意事项:下单时请联系销售核实产品价格及货期,避免后续产生不便,感谢支持!
中文名称
Belnacasan
中文别名
N-(4-氨基-3-氯苯甲酰基)-3-甲基-L-缬氨酰-N-[(2R,3S)-2-乙氧基四氢-5-氧代-3-呋喃基]-L-脯氨酰胺;N-(三甲基-D9-硅烷基)-N-甲基三氟乙酰胺;VX765 抑制剂
英文名称
Belnacasan
英文别名
VX-765;Belnacasan(VX-765);(S)-1-((S)-2-(4-Amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide;Belnacasan;N-(4-Amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxy- 5-oxotetrahydro-3-furanyl]-L-prolinamide;VX765;N-(4-Amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]-L-prolinamide;VX-765(Belnacasan);00OLE78529;VX 765;(2S)-1-[(2S)-2-[(4-amino-3-chlorophenyl)formamido]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide;Be
Cas No.
273404-37-8
分子式
C24H33ClN4O6
分子量
509.00
包装储存
Powder -20°C 3 years;4°C 2 years
详情描述
Belnacasan (VX-765) 是 VRT-043198 的口服生物活性前药,VRT-043198 是有效选择性的 IL 转换酶 (ICE)/caspase-1 抑制剂,对 caspase-1 的 Ki 值为 0.8 nM,对 caspase-4 的 Ki 值小于 0.6 nM。Belnacasan (VX-765) 作用于外周血单核细胞,可抑制 LPS 诱导的 IL-1β 和 IL-18 释放,IC50 约为 0.7 μM。
产品详情
Belnacasan (VX-765) 是 VRT-043198 的口服生物活性前药,VRT-043198 是有效选择性的 IL 转换酶 (ICE)/caspase-1 抑制剂,对 caspase-1 的 Ki 值为 0.8 nM,对 caspase-4 的 Ki 值小于 0.6 nM。Belnacasan (VX-765) 作用于外周血单核细胞,可抑制 LPS 诱导的 IL-1β 和 IL-18 释放,IC50 约为 0.7 μM。
生物活性
Belnacasan (VX-765) is an orally bioactive prodrug of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with K i s of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC 50 of ~0.7 μM.
性状
Solid
IC50 & Target[1][2]
Caspase-1
体内研究(In Vivo)
Belnacasan reduces inflammatory response in murine models of inflammatory disease.
Belnacasan (50-200 mg/kg) significantly reduces serum IL-1β levels by as much as 60%. It is noteworthy that the effect of Belnacasan on the release of IL-1β induced by LPS reached a plateau at 100 mg/kg. Belnacasan (25-100 mg/kg × 2) significantly reduces ear edema. Belnacasan also dose-dependently reduces the concentrations of cytokines, chemokines, and inflammatory mediators in the ear biopsy samples.
Belnacasan (25-200 mg/kg) significantly delays the time to seizure onset by 1.5- to twofold (p<0.01), reduces the number of seizures by 40% (p<0.01) and the total time spent in EEG seizure activity by 30 to 50% (p<0.01). has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005 Aug 15;175(4):2630-4.
[2]. Wannamaker W, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting
溶解度数据
In Vitro: DMSO : 100 mg/mL (196.46 mM; Need ultrasonic)H2O : 1 mg/mL (1.96 mM; ultrasonic and warming and heat to 60°C)配制储备液
搜索质检报告(COA)
[1]. Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005 Aug 15;175(4):2630-4.
[2]. Wannamaker W, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2